Cargando…

Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery

PURPOSE: The purpose of this study was to identify suitable molecular targets for tumor-specific imaging of pancreatic adenocarcinoma. PROCEDURES: The expression of eight potential imaging targets was assessed by the target selection criteria (TASC)—score and immunohistochemical analysis in normal p...

Descripción completa

Detalles Bibliográficos
Autores principales: de Geus, Susanna W. L., Boogerd, Leonora S. F., Swijnenburg, Rutger-Jan, Mieog, J. Sven D., Tummers, Willemieke S. F. J., Prevoo, Hendrica A. J. M., Sier, Cornelis F. M., Morreau, Hans, Bonsing, Bert A., van de Velde, Cornelis J. H., Vahrmeijer, Alexander L., Kuppen, Peter J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093212/
https://www.ncbi.nlm.nih.gov/pubmed/27130234
http://dx.doi.org/10.1007/s11307-016-0959-4
Descripción
Sumario:PURPOSE: The purpose of this study was to identify suitable molecular targets for tumor-specific imaging of pancreatic adenocarcinoma. PROCEDURES: The expression of eight potential imaging targets was assessed by the target selection criteria (TASC)—score and immunohistochemical analysis in normal pancreatic tissue (n = 9), pancreatic (n = 137), and periampullary (n = 28) adenocarcinoma. RESULTS: Integrin α(v)β(6), carcinoembryonic antigen (CEA), epithelial growth factor receptor (EGFR), and urokinase plasminogen activator receptor (uPAR) showed a significantly higher (all p < 0.001) expression in pancreatic adenocarcinoma compared to normal pancreatic tissue and were confirmed by the TASC score as promising imaging targets. Furthermore, these biomarkers were expressed in respectively 88 %, 71 %, 69 %, and 67 % of the pancreatic adenocarcinoma patients. CONCLUSIONS: The results of this study show that integrin α(v)β(6), CEA, EGFR, and uPAR are suitable targets for tumor-specific imaging of pancreatic adenocarcinoma.